Amrize Shares Slide 7.5% as Cut to Full-Year Guidance Overshadows Quarterly Growth
Published on 10/29/2026 at 13:41 | Editorial boerse-global.de
Amrize's stock took a 7.5% hit yesterday after the building materials group trimmed its full-year outlook, a move that shifted investor attention away from solid third-quarter revenue and profit growth and toward the company's more cautious view of the months ahead.
The revised targets are now the yardstick by which the business will be judged. Amrize guided 2026 revenue to $12.2–12.4 billion and adjusted EBITDA to $2.95–3.05 billion. Even the top end of that revenue range sits below the $12.507 billion analyst estimate reported by Reuters, which helps explain why the market reacted so sharply.
Quarterly gains fail to carry through to the bottom line
Revenue for the third quarter of 2026 came in at $3.771 billion, up 2.2% year on year but short of market expectations — meaning the disappointment extends beyond the forward view to the reported period itself. Higher prices, surcharges and contributions from acquisitions underpinned the top line.
Those tailwinds were only partly able to offset higher freight, diesel and raw material costs, along with lower volumes, the company said. Adjusted EBITDA edged up just 0.2% to $1.076 million, lagging the pace of sales growth. Net income, by contrast, rose 3.3% to $558 million — a stronger gain at the earnings level than at the adjusted operating line.
Should investors sell immediately? Or is it worth buying Amrize?
The divergence matters more than the headline sales increase. Extra revenue did not translate into proportionally higher adjusted operating profit, and that gap between top-line momentum and cost pressure is central to how the reduced guidance should be read.
Buyback complete, but the focus stays on operations
Amrize also confirmed yesterday that it had wrapped up its $1 billion share repurchase programme, equivalent to roughly 4% of its share capital. The board intends to cancel the repurchased shares — a distinction worth keeping in mind, since the buyback itself is complete while the cancellation remains a stated intention rather than a done deal.
The capital return sits alongside, not in place of, a more conservative operating plan. It does nothing to alter the lowered business expectations, and on its own it cannot dispel doubts about the revenue outlook. What investors now want to see is how pricing and acquisition contributions can offset higher costs and weaker volumes — the same stress test that links the quarterly performance to the trimmed annual forecast.
A lower bar only helps if it holds
The question facing shareholders is whether the more cautious guidance provides a durable foundation for stabilisation, or whether even the reduced plan understates the drag from cost inflation and higher interest rates — both of which Amrize explicitly cites as burdens. A convincing case would explain why those pressures should remain manageable within the new revenue range. The cut alone does not supply that proof.
Barclays lowered its price target from $55 to $40 on 19 October while reaffirming its neutral rating, according to media reports. That adjustment came before the latest quarterly report and should not be read as a retrospective endorsement of the new guidance.
On the upside, hitting the reduced plan without needing a further downgrade could shift attention from the missed consensus to a more reliable company forecast — not a return to the old consensus, but delivery on the company's own revised promise. On the downside, if cost inflation and higher rates bear down harder than the new plan assumes, fresh uncertainty over the annual targets would weigh heavily on confidence in management's forecasting, given that one cut has already been made.
Amrize at a turning point? This analysis reveals what investors need to know now.
Webcast and dividend dates ahead
The next concrete checkpoint is today's webcast on the quarterly results, scheduled for 7:30 a.m. Central Time. Investors will be listening for how Amrize justifies the resilience of its reduced revenue range and for any detail that clarifies the assumptions behind it.
Dividend dates are also on the calendar: a quarterly payout of $0.11 per share, with an ex-dividend and record date of 10 November and payment scheduled for 18 November.
For the operational picture, though, the guidance remains decisive. Should Amrize credibly back up the new range, the confidence base could steady. If its achievability comes into question again, the debate over further downside risks is likely to return.
Ad
Amrize Stock: New Analysis - 29 October
Fresh Amrize information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
